EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis

Harpreet S Bhatia iD, Simon Wandel iD, Peter Willeit iD, Anastasia Lesogor, Keith Bailey, Paul M Ridker iD, Paul Nestel iD, John Simes iD, Andrew Tonkin iD, Gregory G Schwartz iD, Helen Colhoun, Christoph Wanner iD und 1 weitere

Circulation · 28.01.2025 · 151 (4) · 312-321

DOI: 10.1161/circulationaha.124.069556 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Circulation, erschienen am 28.01.2025. Verfasst von Harpreet S Bhatia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, University of California, San Diego, La Jolla (H.S.B., S.T.). Hauptthemen laut MEDLINE: Lipoprotein(a), Cholesterol, LDL, Cardiovascular Diseases. Die Arbeit wurde bisher 127-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD). However, the relationship between Lp(a) level, LDL-C level, and ASCVD risk at different thresholds is not well defined. METHODS: A participant-level meta-analysis of 27 658 participants enrolled in 6 placebo-controlled statin trials was performed to assess the association of LDL-C and Lp(a) levels with risk of fatal or nonfatal coronary heart disease events, stroke, or any coronary or carotid revascularization (ASCVD). The multivariable-adjusted association between baseline Lp(a) level and ASCVD risk was modeled continuously using generalized additive models, and the association between baseline LDL-C level and ASCVD risk by baseline Lp(a) level by Cox proportional hazards models with random effects. The joint association between Lp(a) level and statin-achieved LDL-C level with ASCVD risk was evaluated using Cox proportional hazards models. RESULTS: Compared with an Lp(a) level of 5 mg/dL, increasing levels of Lp(a) were log-linearly associated with ASCVD risk in statin- and placebo-treated patients. Among statin-treated individuals, those with Lp(a) level >50 mg/dL (≈125 nmol/L) had increased risk across all quartiles of achieved LDL-C level and absolute change in LDL-C level. Even among those with the lowest quartile of achieved LDL-C level (3.1–77.0 mg/dL), those with Lp(a) level >50 mg/dL had greater ASCVD risk (hazard ratio, 1.38 [95% CI, 1.06–1.79]) than those with Lp(a) level ≤50 mg/dL. The greatest risk was observed with both Lp(a) level >50 mg/dL and LDL-C level in the fourth quartile (hazard ratio, 1.90 [95% CI, 1.46–2.48]). CONCLUSIONS: These findings demonstrate the independent and additive nature of Lp(a) and LDL-C levels for ASCVD risk, and that LDL-C lowering does not fully offset Lp(a)-mediated risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein(a)Cholesterol, LDLCardiovascular DiseasesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleFemaleRisk FactorsMiddle AgedRandomized Controlled Trials as TopicAged

Stichwörter der Autor:innen

cholesterolheart disease risk factorslipoprotein(a)lipoproteins, LDL

Substanzen

Lipoprotein(a)Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, University of California, San Diego, La Jolla (H.S.B., S.T.).
  • Novartis Pharma AG, Basel, Switzerland (S.W., A.L., K.B.).
  • Department of Medical Statistics, Informatics and Health Economics at the Medical University of Innsbruck, Austria (P.W.).
  • Brigham and Women's Hospital, Harvard Medical School, Boston, MA (P.M.R.).
  • Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (P.N.).
  • NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia (J.S.).

ORCID-Profile: Harpreet S Bhatia, Simon Wandel, Peter Willeit, Paul M Ridker, Paul Nestel, John Simes, Andrew Tonkin, Gregory G Schwartz, Christoph Wanner, Sotirios Tsimikas

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Bhatia, H. S., Wandel, S., Willeit, P., Lesogor, A., Bailey, K., Ridker, P. M., Nestel, P., Simes, J., Tonkin, A., Schwartz, G. G., Colhoun, H., Wanner, C., & Tsimikas, S. (2025). Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis. Circulation, 151(4), 312-321. https://doi.org/10.1161/circulationaha.124.069556

Vancouver

Bhatia HS, Wandel S, Willeit P, Lesogor A, Bailey K, Ridker PM, et al. Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis. Circulation. 2025;151(4):312-321. doi:10.1161/circulationaha.124.069556

BibTeX
@article{Bhatia2025,
  author = {Bhatia, Harpreet S and Wandel, Simon and Willeit, Peter and Lesogor, Anastasia and Bailey, Keith and Ridker, Paul M and Nestel, Paul and Simes, John and Tonkin, Andrew and Schwartz, Gregory G and Colhoun, Helen and Wanner, Christoph and Tsimikas, Sotirios},
  title = {Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis},
  journal = {Circulation},
  year = {2025},
  volume = {151},
  number = {4},
  pages = {312--321},
  doi = {10.1161/circulationaha.124.069556}
}
Kostenlos starten →